Document is current
Any future updates will be listed below
-
Authors
Bhanpattanakul, Sudchaya
Buranapraditkun, Supranee
Kaewamatawong, Theerayuth
Teewasutrakul, Patharakrit
Sirivisoot, Sirintra
Poonsin, Panida
Rungsipipat, Anudep
Phakdeedindan, Praopilas
Nakagawa, Takayuki
Sailasuta, Achariya
Tharasanit, Theerawat
-
Funding
Funding for this research was provided by:
the National Research Council of Thailand (N41D640002, N41D640002)
the Chulalongkorn University Graduate Scholarship to the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship
The 90th Anniversary of Chulalongkorn University
Rachadapisek Sompote Endowment Fund 2019 (CU_GR_62_77_31_07, CU_GR_62_77_31_07)
the Center of Excellence for Companion Animal Cancer
- License Information
-
More Information
Article History
Received: 21 September 2023
Accepted: 16 February 2025
First Online: 6 March 2025
Declarations
:
: The clinical and experimental protocols were approved by the Chulalongkorn University of Animal Care and Use guidelines (protocol no.2131049). The biosafety procedure for cell approaches was approved and performed with the permission of the Biosafety Committee of the Faculty of Veterinary Science, Chulalongkorn University (protocol no. 2031029). The owners of the patients described in this article, who underwent surgical treatment for canine cutaneous MCT, were informed and required to sign treatment consent forms prior to receiving treatment.
: Not applicable.
: The authors declare no competing interests.
